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Permethric acid derivativesa b s t r a c t
Stringent requirements are in place for the evaluation and registration of new compounds with biocidal
or pesticidal activities. However, the registration requirements for established compounds from new sup-
pliers or for established compounds produced by a different manufacturing process have been less clear
and ambiguity exists as to how ‘equivalence of health hazards’ can unequivocally be demonstrated ana-
lytically and by toxicological assays. The case presented in this analysis focuses on the chiral pyrethroid
transﬂuthrin (TFL) synthesized by esteriﬁcation of an acid chloride and alcoholic moiety. According to
any modiﬁcations of the process of synthesis and puriﬁcation, new potentially highly toxic and yet chem-
ically reactive impurities in low concentrations (<0.1%) may be formed. Amongst these, that with the
structural alert ‘organic acid anhydride’ was given heightened concern as the most potent putative tox-
icologically signiﬁcant impurity. The course taken in this analysis focused on the comparison of reference
TFL with commercialized generic TFL from two alternative manufacturing sources in India and China.
Despite their apparent high racemic purity, TFLs from generic sources were biologically less effective,
genotoxic in the Ames’ assay, demonstrated sensory lung irritation and lung/skin sensitization in special-
ized bioassays. While the off-patent reference TFL was unequivocally negative in all assays (anhydride
content not detectable, LOQ <0.01%), positive results with high batch-to-batch variability were a frequent
outcome in generic TFLs. Tier I analytical assays failed to detect this relevant impurity in the absence of
impurity-speciﬁc optimized analytical procedures. This ﬁnding suggests that a well-balanced combined
approach of analytical and toxicological assays provides the best means to assure that all critical impu-
rities are identiﬁed and accounted for. Similarly, putative ‘structural alert’-based toxicity tests proved to
be more predictive than any indiscriminant battery of standard bioassays commonly applied to demon-
strate equivalence, such as acute oral/dermal toxicity and/or eye/skin irritation assays.
 2014 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction
When registering a new active ingredient for pesticidal use, it is
incumbent on manufacturers who manufacture the technical
material to supply a well-deﬁned set of information. This includes
an extensive set of physico-chemical, analytical, and toxicological
data in order to characterize the intrinsic hazards of the active
ingredient. For active substances to be used as household insecti-
cide these data are complemented further by subchronic inhalation
bioassays as this route of exposure mirrors that of the consumer
most. When reaching the off-patent state, alternative (generic)
manufacturers’ may demonstrate equivalence to the originalregistered active substance by analytical data (Tier I) and subse-
quent waiving of the requirement to generate any additional toxic-
ity data (Tier II). This approach implicitly assumes that any
constituent of an active substance can be identiﬁed analytically
with a sufﬁcient overall sensitivity and speciﬁcity. This assumption
is subject to challenge under circumstances where highly reactive
impurities are present but remain undetected by non-specialized
analytical methods. Such impurities may exert high and/or speciﬁc
pulmonary toxicity upon inhalation. Their disclosure requires an
in-depth understanding of the production process of the active
substance as well as an integrated ‘structural alert’-based toxicity
testing approach. These include but are not restricted to sensory/
pulmonary irritation, lung/skin sensitization, and genotoxicity
testing keeping in mind that any aqueous testing system contain-
ing nucleophiles may neutralize/destroy such reactive impurities.
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levels in other manufacturers’ alternative products whereas it may
be considered unnecessary to include these in the speciﬁcation of
the innovator active substance (reference active), if absent. For
impurities posing a similar type of toxic hazard to that of the active
ingredient [additive effects], the maximum acceptable limit
adopted by FAO and WHO (2010) normally corresponds to a con-
centration which would lead to a calculated 10% increase in the
overall hazard presented by the active ingredient. However, where
effects are not considered to be additive such limits have to be cal-
culated on a case-by-case basis (FAO and WHO, 2010). Non-
additive, chemically reactive relevant newly formed impurities
may not necessarily be detected by Tier I methods optimized to
quantify the active substance rather than relevant reactive impuri-
ties. Likewise, acute standard toxicological (Tier II) assays with
reactive impurities, may not necessarily identify unexpected toxi-
cological proﬁles when using gastrointestinal routes of exposure.
Somewhat similar two-tiered approaches are also used by other
regulations (EEC, 2011; ECHA, 2013; GHS, 2013). In order to
observe current animal welfare regulations there is a common
trend of all regulatory codes to preferentially stratify Tier II-level
studies case-by-case expert knowledge-based. This means, for
any manufacturing process, the putative spectrum of impurities
has to be assessed by structure–activity and mode-of-action
(MoA)-based analyses. This information can serve as starting point
for identifying ‘structural alerts’ to further reﬁne in vivo testing
procedures with fewer animals.
The case presented in this analysis focuses on the type I pyre-
throid transﬂuthrin (TFL) which is synthesized by using two major
building blocks: tetraﬂuorobenzyl alcohol and trans-2,2-dimethyl-
3-(2,2-dichlorovinyl)-cyclopropanecarboxylate. It can be synthe-
sized in several ways, starting from reactions of optically active
1R-trans-permethric acid chloride or derivatives thereof with the
tetraﬂuorobenzyl alcohol (Fig. 1). Usually milder conditions for
nucleophilic displacement esteriﬁcation are necessary in these
types of reactions with intermediates bearing leaving groups.
Alternative syntheses may use a chloroformate derivative of the
alcohol to react with the carboxylate to give a mixed anhydride
which decomposes yielding the desired ester (Naumann, 1990).
Hence, the de novo in situ formation of anhydride-like impurities
appears to be underappreciated by default. Therefore, to exclude
their presence, highly reﬁned analytical methods are needed, ide-
ally complemented by MoA-based toxicological feed-back loops.
The stability of such highly reactive impurities depends on solvent
properties and puriﬁcation steps which may change from one
manufacturer to another.Fig. 1. Chemical structure of R/S-enantiomers of transﬂuthrin. BTFL is used in as highly selective, low-toxicity household insec-
ticide with exposure proﬁles ranging from high & acute (e.g., aero-
sols) to low & long-term (e.g., evaporator systems, mosquito coil
smoke). This means, exposure to the active substance occurs pref-
erentially via the inhalation route with minimal possibilities of
degradation of airborne reactive relevant impurities as could be
expected following dissolution in aqueous vehicle systems or
administration via the gastrointestinal tract. Accordingly, the inha-
lation route is not only the most direct route of exposure, it also
mirrors the actual consumer exposure best (Vesin et al., 2013).
Accordingly, this route seems to be most apt of identifying and
integrating the adversity of reactive impurities in the absence of
decomposition reactions that would conceal their presence.
The objective of this comparative study was to examine nine
commercialized generic samples of TFL (active substance) from
two major alternative sources of TFL in India and China collated
in different Asian regions over a time period of approximately
1 year. The TFL-reference was from Bayer CropScience (BCS), Ger-
many. Two independent laboratories were involved to execute
selected ‘structural-alert’-based and standard toxicological qualiﬁ-
cation tests for the following endpoints: (i) respiratory tract sen-
sory irritation and neuroexcitation, (ii) eye/skin irritation, (iii)
skin sensitization, and (iv) bacterial reverse mutation tests. This
battery of tests was complemented by bioequivalence tests in mos-
quitoes under differing testing conditions. The skin sensitization
test was supplemented by a respiratory sensitization assay with
pure permethrinic acid anhydride (PAA), a putative chemically
reactive impurity at very low level (<0.1–1%) which exhibits struc-
tural alerts for both local irritation and skin/lung sensitization. Suf-
ﬁce it to say, the quantiﬁcation of PAA is analytically challenging
and PAA-speciﬁc toxicity to reveal seems equally challenging in
the matrix of a biologically active substance.2. Methods
2.1. Test material and reagents
Bayothrin (transﬂuthrin, abbreviated TFL; 2,3,5,6-Tetraﬂuoro
benzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane-
carboxylate; CAS-No. 118712-89-3) is an insecticidal active sub-
stance developed by Bayer CropScience (BCS), Germany. Generic
TFLs were from alternative sources in India and China (two differ-
ent manufacturers, see Table 1). All test specimens were
re-analyzed in accordance to a published, WHO-recommended
achiral gas chromatographic (GC) method with Flame Ionizationioefﬁcacy is dependent on the purity of the R-enantiomer.
Table 1
Source of test specimen and analytical composition.
Substance Source Purity re-analysis Permethrinic acid %c Permethrinic acid anhydride % Unknown impurities/total impurities %d
TFL-R BCS 98.2% 1R-transa <0.03a <0.01 (LoD)a 0.36a/–b
+<1.0% 1S-trans
TFL-GI India 95.6% 1R-transa 0.003a 0.01a 0.39a/–b
+2.5% 1S-trans
TFL-GII India 95.0% 1R-transa 0.015a 0.04a 0.46a/–b
+2.9% 1S-trans
TFL-GIII India 95.6% 1R-transa 0.006a <0.01 (LoD)a 0.47a/–b
+2.3% 1S-trans
TFL-GIV China 91.7% 1R-transa 0.05a 0.6a 0.52a/–b
+4.4% 1S-trans
TFL-GV China 92.8% 1R-transb 0.55a/0.26b 0.12a/n.d.b 0.68a/2.06b
3.7% 1S-trans
TFL-GVI India 96.8% 1R-transb <0.1a/0.0b 0.02a/n.d.b <0.1a/0.38b
1.9% 1S-trans
TFL-GVII India 47.8% 1R-transb –/<0.43b –/n.d.b –a/3.47b
47.8% 1S-trans
TFL-GVIII India 97.7% 1R-transb <0.1a/0.0b 0.014a/n.d.b 0.44a/0.57b
0.8% 1S-trans
TFL-GIX India 51.2% 1R-transb <0.1a/0.0b <0.01a/n.d.b 0.6a/2.41b
45.9% 1S-trans
Analytical and toxicological data were provided by Bayer Corp Science (a) and Sumitomo Chemicals (b); (c) weight/weight; (d) #a/#b: the nomenclature used for impurities in
laboratory (a) and (b) were either expressed as total impurities or unknown impurities; TFL-R: Bayothrin technical active substance (BCS; Bayer Crop Science, Germany); the
regional samples were from the same regional producer using different samples collated over 1 year. LoD: Limit of detection, n.d.: not detectable, ‘–’: not determined.
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during the Research & Development of the reference TFL using
external standards. This ‘innovator’-based analytical methods were
suitable for the determination of the diastereomeric purity of TFL,
and were analytically optimized to identify all signiﬁcant and tox-
icologically relevant by-products at a limit of detection <0.01%,
depending on the toxic potency of the putative impurity. Calibra-
tion substances with veriﬁed identity and declared content were
used for reference and when not available conﬁrmation was sought
by GC–MS/EI using an Agilent MSD under slightly modiﬁed
conditions (for additional details see http://www.who.int/whopes/
quality/Transﬂuthrin_eval_only_Nov2006.pdf).
2.2. Animals
Healthy young adult male Speciﬁc Pathogen Free (SPF) bred
Wistar rats, strain Hsd Cpb:WU (SPF), from the experimental
animal breeder Harlan–Nederland (NL), AD Horst, were used in
inhalation studies. At the commencement of the study the rats
were 2–3 months old and were acclimatized for 1 week prior to
the beginning of study. Rats were singly housed in poly carbonate
cages, containing low-dust wood shavings as bedding material.
Ration consisted of a standard ﬁxed-formula diet and tap water
(drinking bottles). Guinea pigs (strains: DHPW or Hartley) were
used for the Maximization Test (GPMT) and respiratory sensitiza-
tion test. Both food and water were available ad libitum. Male
rabbits (Strain: New Zealand White) were used for eye and skin
irritation tests. Rabbits were fed with ca. 120 g/day of the diet
and had free access to water. Housing conditions were in accor-
dance to the EU or Japanese animal welfare regulations. Animal
holding rooms had a dark/light cycle 12 h/12 h. Temperature and
relative humidity of animal holding rooms were in the range of
20–24 C and 30–70%, respectively.
The studies were performed in animal care-approved laborato-
ries in accordance with either the German Animal Welfare Act and
European Council Directive 2010/63/EU or the Japanese equivalent.
All studies observed the procedures called for by current interna-
tionally harmonized testing guidelines.2.3. Rationale of experimental protocols
Minimal standards for demonstrating equivalence of generic
and references substances include the following toxicological tests
(EEC, 2011): a bacterial reverse mutation assay (Ames’ test) unless
there are clear indications that another type of genotoxicity test
might be a more appropriate, an acute oral study, and/or skin sen-
sitization study (local lymph node assay normally preferred), and/
or reproduction/developmental toxicity screening test are called
for either with technical material from the new source or the
respective impurity. This approach makes some assumptions that
may not always be met: e.g. (i) it is presumed that toxicity is driven
by systemic effects and that dermal, oral and inhalation absorption
is comparable to the reference active substance; (ii) the behavior of
the impurity is comparable to the reference active substance.
Both prerequisites are not fulﬁlled for chemically reactive
impurities, as their toxicity is elicited at the portal-of-entry and
adverse outcome pathways can only be revealed by inhalation
and possibly also by dermal administration. Accordingly, the
course taken in this study was follows:
 Ames’ assay in twomodiﬁcations to allow for possible inactivat-
ing side-reactions of reactive impurities.
 Standard eye/skin irritation tests in rabbits.
 Acute inhalation test in rats supplemented by lung function
measurements for revealing lower and upper respiratory tract
sensory irritation at non-neuroexcitatory and neuroexcitatory
exposure levels.
 Dermal sensitization tests using the guinea pig Maximization
Assay (GPMT) (Magnusson, 1980; Magnusson and Kligman,
1969).
 Proof-of-principle tests for dermal and lung sensitization with
permethrinic acid anhydride (PAA) in guinea pigs. Organic
anhydrides have been demonstrated to be very potent skin
and respiratory sensitizers (Pauluhn, 2003a; Pauluhn and
Mohr, 2005; Pauluhn et al., 1999, 2002). These chemicals
can react with proteins to form antigenic complexes that
induce speciﬁc immune responses (Tarlo et al., 2011). An
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demonstrated for other reactive, asthmagenic electrophilic
chemicals (Pauluhn, 2014).
PAA is a putative by-product of TFL when using production pro-
cesses and/or intermediates not optimized to eliminate its pres-
ence. Due to its structural alert, PAA is predestined to be both a
skin and respiratory sensitizing agent falling into the category of
‘substance of very high concern (SVHC)’ due to the ‘equivalent level
of concern’ policy set out in REACH Article 57(f). Previously vali-
dated approaches (Pauluhn, 1997; Pauluhn and Mohr, 1994,
1998) were taken to assess the respiratory sensitization potential
in guinea pigs using intradermal induction followed by an inhala-
tion challenge with permethrinic acid anhydride–Guinea pig
serum albumin conjugate (PAA–GPSA).
2.4. Respiratory sensitization – PAA
Guinea pigs were intradermally induced with PAA on days 0, 2,
and 4 (injection volume: 100 lL/injection, 2.5% solution in acetone
as vehicle). All animals were challenged by inhalation on day 21
with the PAA–GPSA-conjugate aerosol (0.75% w/w solution of pro-
tein-conjugate dissolved in saline; breathing zone concentration
33 mg/m3, MMAD (mass median aerodynamic diameter) 1.5 lm;
geometric standard deviation, GSD, 2.4). The duration of challenge
was for 30 min followed by a post-challenge data recording period
for lung function of 30 min. One day after challenge all animals
were subjected to gross necropsy and lung and lung-associated
lymph nodes were immersed in buffered formaldehyde, embedded
in parafﬁn, stained with H&E and examined by light microscopy.
The protocol and methodology applied were similar to those pub-
lished in details elsewhere (Pauluhn, 1997). The antigenicity of the
synthesized GPSA-conjugate as well as the concentration of PAA
required to induce anti-PAA IgG1 serum antibodies were deter-
mined as described below. The intradermal threshold dose was
determined that does not increase anti-IgG1-PAA-related serum
anti-bodies.
2.4.1. Synthesis and characterization of the PAA–GPSA conjugate
The PAA–GPSA conjugate was synthesized and characterized as
follows: 2.0 g of guinea pig serum albumin (GPSA) (obtained from
Sigma, Deisenhofen, Germany) were dissolved in 200 mL of PBS
(10 mM sodium phosphate pH 7.4 containing 150 mM sodium
chloride). Within 15 min a solution of 2.4 g of PAA in 2.0 mL of ace-
tone was slowly added. Stirring was continued for additional
70 min. To this solution 20 mL of trichloroacetic acid (72% w/v)
were added, and the mixture was stirred at 4 C overnight. The
reaction mixture was centrifuged at 4000 rpm (Minifuge T, Herae-
us, Offenbach, Germany) for 20 min at 4 C, the supernatant was
then discarded and the pellet dissolved in 100 mL of ammonium
bicarbonate buffer (50 mMol). This solution was dialyzed for 48 h
against four changes of ammonium bicarbonate buffer. Finally,
the conjugate was lyophilized (yield: 1.84 g) and stored at 20 C
until use. An inhibition ELISA was essentially performed in the
same way as the normal ELISA which was conducted to determine
the serum titers. The wells of a microliter plate were coated with
PAA–GSA conjugated diluted serum samples. Permethrinic acid
(Bayer AG, Leverkusen, Germany) dissolved in DMSO was added
to attain ﬁnal concentrations ranging from 1000 pg/mL to
0.01 pg/mL. The mixture of guinea pig sera and permethrinic acid
was incubated for 1.5 h followed by ELISA as described above. To
exclude any unspeciﬁc effects of permethrinic acid on the ELISA
procedure per se, a control ELISA was performed with a mouse-anti
rat serum albumin antibody using a microliter plate coated with
rat serum albumin (obtained from Sigma, Deisenhofen, Germany)
at 10 pg/mL in PBS at +4 C overnight. The following next day, asolution of a monoclonal mouse–anti rat serum albumin antibody
(clone 4.32, prepared in house; 25 ng/mL, 100 pL per well) was
added and mixed with permethrinic acid dissolved in DMSO (in
the same concentration range as described above). This ELISA
was conducted as described above with the exception that a
goat–anti mouse immunoglobulin peroxidase conjugate (dilution
1:1000, obtained from Sigma, Deisenhofen, Germany) was used
to quantify bound antibody.2.4.2. ELISA of serum samples
Bloodwas obtained from all animals of this study by heart punc-
ture at necropsy. Blood clots were removed by centrifugation after
30 min at ambient temperature (15 min, 4000 rpm; Minifuge T,
Heraeus, Offenbach, Germany, 4 C). ELISA plates (Nunc, Wiesba-
den, Germany) were coated overnight with 100 pL/well of perme-
thrinic acid–guinea pig serum albumin conjugate (PA–GSA) at
20 pg/mL in PBS. On the next day the plates were washed 5-times
with PBST (PBS containing 0.05% Tween-20, Sigma, Deisenhofen,
Germany) and blocked with 200 pL/well of PBST with 3% non-fat
dry milk powder (ICN Biochemicals, Meckenheim, Germany) for
1.5 h. Subsequently the plates were washed 5-times and the guinea
pig serum samples were added (100 pL/well in triplicate covering a
dilution range from 1:10 to 1:107). After incubation for 1.5 h the
plates were washed 5-times, and the secondary antibody was
added (rabbit–anti guinea pig IgGi, Biogenzia, Bochum, Germany)
at a dilution of 1:2000. After incubation for 1.5 h the plates were
washed 5-times, and a goat–anti rabbit IgG-peroxidase conjugate
(Sigma, Deisenhofen, Germany) was added at a dilution of 1:1150.
After incubation for 1.5 h the plates were washed 5-times, and
the substrate solution added (20 mg o-phenylenediamine (Sigma)
and 20 pL hydrogen peroxide (30%, Merck, Darmstadt, Germany)
in 25 mM citric acid/50 mM di-sodium phosphate pH 5.3). After
5–10 min the reaction was stopped by the addition of 50 pL 4 M
sulfuric acid, and the optical density was read at 490 nm. Hence,
the immunochemically characterized PAA–GSA conjugate
demonstrated that this conjugate only reacted with sera from
PAA-induced guinea pigs, and not with sera from naïve controls.
The antigen–antibody reaction occurring between the PAA–GSA
conjugate and sera from sensitized guinea pigs could be inhibited
by free permethrinic acid at 1000 lg/mL. In a control experiment,
permethrinic acidwas not able to affect this antigen–antibody reac-
tion. Thus, these two experiments provide robust evidence that the
PAA–GSA conjugate contains permethrinic acid-speciﬁc epitopes of
haptenated guinea pig serum albumin. Due to the limited amount
of PAA-conjugate available for inhalation challenge exposures,
more extended comparisons were technically not feasible by the
inhalation route.2.5. Skin sensitization
Two experimental set-ups were selected to better understand
the cause of TFL-related skin sensitization. Pre-technical TFL and
TFL spiked with 1% PAA and examined for their skin-sensitizing
properties in the guinea pig Maximization Assay (GPMT) according
to OECD, 1992#406 apart from a second re-challenge with TFL pre-
technical applied after induction and challenge with 1% PAA as
detailed in Table 2. Epicutaneous induction followed using a repeat
topical challenge regimen with the neat test specimens. Topical
administrations utilized a hypoallergic dressing soaked with
0.5 mL of the neat test substance with occlusive exposure for 24-
h. The skin-sensitizing properties of the generic TFLs (see Table 1)
were compared using the GPMT. Depending on the outcome of
prior dose-ﬁnding studies, well-rationalized concentrations of
TFL in corn oil, acetone, petrolatum or Cremophor EL were used
(for details see Table 2).
Table 2
Concentrations used for inductions and challenge in GPMT.
Substance Inductions Challenge
Intradermal Epicutaneous
TFL-R pre-technicala 1% in Cremophorb Neat Neat
TFL-R pre-technical spiked with 1%PAAa 1% in Cremophorb Neat TFL1% PAA 1st Challenge with neat TFL1%PAA
2nd Challenge with neat TFL pre-technical
TFL-R 1% in Cremophorb Neat Neat
TFL-GIV 5% PEG 400c Neat Neat
TFL-GV 5% in corn oil Neat Neat
TFL-GVI 5% in corn oil Neat 10% in acetone
TFL-GVII 5% in corn oil 50% in petrolatum 0.2% in petrolatum
TFL-GVIII 5% in corn oil Neat Neat
TFL-GIX 5% in corn oil Neat Neat
a TFL-R spiked with permethrinic acid anhydride (PAA).
b Cremophor EL 2% solution in saline.
c PEG: polyethylene glycol.
82 J. Pauluhn, K. Ozaki / Regulatory Toxicology and Pharmacology 71 (2015) 78–922.6. Eye and skin irritation studies
In order to evaluate the eye and skin irritation potency of gen-
eric TFLs, the irritation studies were conducted in accordance with
OECD, 2002-guideline #404/405 and US-EPA, 1998a,b, 2003 OPPTS
#870-2400/-2500, except the number of employed animals. Each
generic TLF was applied to skin and eye of rabbits, and then skin
and eye reactions were scored according to Draize method
(Draize et al., 1944).2.7. Respiratory tract sensory irritation studies
Sensory irritation is considered the ﬁrst integrated manifesta-
tion of a response caused by portal-of-entry-related sensory irrita-
tion and/or central nervous system (CNS)-mediated
neuroexcitation. It was assumed that the former is evoked by
site-of-deposition-dependent reﬂex-stimulation whereas the latter
may originates from CNS-stimulation. Hence, respiratory tract-
reﬂexes are expected to be superimposed by neuroexcitatory
reﬂexes at higher exposure concentrations. Changes in breathing
frequency and tidal volume were considered to be reﬂective of
‘upper’ and ‘lower’ respiratory tract sensory irritation, respectively.
Ancillary pre-studies with four different batches of reference TFL
(TFL-R) were compared with the TFL-R used in this study. A target
concentration of approximately 200 mg/m3 was selected to exam-
ine a distinct level of sensory irritation typical of a type I pyre-
throid in the absence on CNS-related toxicity. A mixed response
of sensory irritation and neuroexcitatory activity was expected to
occur at about 400 mg/m3. This was evidenced by mild and rapidly
reversible tremors, seizures and superﬁcial fasciculations (only
observed by the functional measurements during exposure). At
neuroexcitatory concentrations, the breathing patterns became
increasingly aberrant and neuroexcitatory stimulation interfered
with the analysis of breathing patterns as shown in Fig. 2, lower
panel. In fact, the software for data-analysis as an additional or
unaccountable aberrant breathing cycle identiﬁed the tremors
and/or fasciculations. Therefore, the outcome of the breathing pat-
tern analysis at 400 mg/m3 appears to be more a reﬂection of gen-
eral neuroexcitation rather than any quantiﬁable analysis of
breathing patterns.
After acclimatization baseline parameters were recorded for
approximately 15 min (exposure to air). The duration of exposure
to TFL was 45 min, followed by an air-only post-exposure period
of 30 min. Measurements were made simultaneously using four
(comparison of different generic TLFs) or six (comparison of differ-
ent batches of reference TFL) Wistar rats per exposure. For evalua-
tion of reactions occurring during the inhalation exposure periodthe focus was on the measurement of respiratory rate and tidal vol-
ume. Measurements were made on spontaneously breathing, con-
scious rats in modiﬁed nose-only exposure tubes that were used as
volume displacement plethysmographs (p = const.) equipped with
a wire–mesh style pneumotachograph and a differential pressure
transducers (MP 45 ± 2 cm H2O, Validyne) ﬁtted shortly onto the
plethysmograph. The validation of the system was performed prior
to each exposure for all plethysmographs using deﬁned calibration
volumes and frequency in the range typical of rats. For data acqui-
sition, analysis and archival a Ponemah system was used (Data Sci-
ence International, DSI, Valley View, OH, USA). Further details of
this method have been published elsewhere (Li and Pauluhn,
2010).2.7.1. Generation of inhalation exposure atmospheres
In order to attain a high and temporally stable concentration of
the aerosolized active substances, a modiﬁed BGI 3-nozzle collison
nebulizer (Type CN-25 MRE, BGI Inc., Waltham MA, USA) was used
to nebulize 3% and 6% solutions of the actives in polyethylene gly-
col (PEG) 400. For decreasing the viscosity of PEG400 the temper-
ature of the nebulizer was maintained at 35 C (digitally controlled
water bath and jacketed reservoir). Nebulization used conditioned,
pressurized air (15 L air/min; dispersion pressure approximately
500 kPa). This atmosphere was directly entrained into the inhala-
tion chamber without additional dilution of air. Details related to
actual concentrations and particle size are summarized in Table 3.
An URG cyclone (10 L, 2.5 lm) was used to optimize the aerosoli-
zation process. The test atmosphere generation conditions pro-
vided an air exchanges rate of 237 per hour. Temporally stable
equilibrium concentrations (t95) were attained in less than 1 min
as evidenced by real-time aerosol monitoring of chamber atmo-
spheres. Temperature and humidity are measured continuously
yielding 22 C and 5%, respectively. At each exposure port a mini-
mal air ﬂow rate of 0.75 L/min was provided. The 90% of the supply
air was extracted via the exhaust and sampling ports (computer
controlled). Measured air-ﬂows were calibrated with precision
ﬂow-meters and/or specialized ﬂow-calibration devices (Bios Dry-
Cal Defender 510 (http://www.smglink.com/bios/drycal_defender/
drycal defender.html) and TSI Model 4043 Mass Flow meter
(http://www.tsi.com/en-1033/models/3472/4043.aspx)) and were
checked for correct performance at regular intervals. Aerosol
scrubbing devices were used for exhaust air clean-up. All inhala-
tion chamber variables were controlled and recorded by a Data
Acquisition and Control System. The exposure chambers were
accommodated in adequately ventilated enclosures. Details of this
nose-only exposure system, including its validation, have been
published (OECD GD#39, 2009; Pauluhn and Thiel, 2007).
Fig. 2. Analysis of respiratory patterns of rats in volume displacements nose-only plethysmographs. Upper and lower analog tracings represent ﬂow- and volume-derived
changes, respectively (X-axis: 200 ms/tick). The breath structure is characterized by three phases: inspiratory time (IT), expiratory time (ET), and apnea time (AT). These
phases can be used to distinguish between upper respiratory tract irritants (bradypnea period between IT and ET as shown in the left panel) and lower respiratory tract
irritants (apnea period between end of ET and start of new breath as shown in the right panel). All TFLs were aerosolized in a non-volatile, non-irritant vehicle (Table 3). At
200 mg TFL/m3 breathing patterns can be attributed to sensory irritation (lower left panel) whereas at 400 mg TFL/m3 they may be superimposed by neuroexcitatory
stimulation which confounds the breath-recognition by the applied software (lower right panel). Vertical lines represent the ﬂags for breath-recognition set by the software
applied.
Table 3












200 8314 182.7 1.12 (1.87)
400 8730 392.8 1.10 (1.86)
TFL-I
200 8134 185.6 1.08 (1.86)
400 8277 464.2 1.11 (1.86)
TFL-II
200 8258 196.4 1.11 (1.84)
400 8524 420.0 1.13 (1.84)
TFL-III
200 8671 206.6 1.20 (1.76)
400 8638 408.3 1.14 (1.85)
TFL-IV
200 8127 214.9 1.10 (1.84)
400 8311 408.1 1.18 (1.79)
Vehicle 8510 – 1.13 (1.84)
Vehicle: Polyethylene glycol 400 (PEG400) from Sigma–Aldrich (Prod#: 81172).
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Total mass concentration was determined by gravimetric anal-
ysis (ﬁlter: Glass-Fiber-Filter, Sartorius, Göttingen, Germany).
Actual concentrations of TFL in the breathing zone areas of rats uti-
lized gas chromatography (GC) with electron capture (EC)-detec-
tion. Speciﬁed TFL served as external standard. Gas
chromatography (HP 6890) data were integrated and processed
server based (Chromato graphic Data System from Waters
equipped with Impower2 Software and MS Windows). The qualiﬁ-
cation of the analytical method was conﬁrmed in terms of linearity,
selectivity, precision and stability of the Analyte. Atmosphere sam-
ples are trapped on glass ﬁber ﬁlter (same matrix as used for totalmass concentrations which included PEG400). The analyte was
eluted with toluene, the same solvent as used to prepare stock
solutions. Chromatography utilized fused-silica columns (Ultra-2
25 m  0.32 mm  0.17 lm) at injector/detector temperatures of
200 C/250 C (oven 80 C at 1 min; with 20 C/min ramped to
250 C). Particle size analyses utilized a low-pressure critical oriﬁce
Berner-Type AERAS LPI type stainless steel 9-stage cascade impac-
tor (HAUKE, Gmunden, Austria). The individual impactor stages
were covered by aluminum foil and glass ﬁber ﬁlter. The mass
median aerodynamic diameter (MMAD) and the geometric stan-
dard deviation (GSD) were calculated as described previously
(Pauluhn, 2005). Active volumetric ﬂow control is maintained by
mass ﬂow controllers whose set points are on-line adjusted in
accordance with the measured ambient temperature and pressure.
All samples were taken from the vicinity of the rats’ breathing
zone.
2.8. Genotoxicity
Nine samples of TFL from two alternative sources were exam-
ined for point mutations in bacteria: Salmonella typhimurium
strains TA100, TA1535 and Escherichia coli (WP2uvrA), for base-
pair substitutions and frame-shift mutations: S. typhimurium
TA98 and TA1537. The experiments were performed according to
OECD Guideline TG#471 (OECD, 1997) in the absence and presence
of an extrinsic metabolizing S9-system (Bayer: pre-incubation
with/without S9 from Aroclor 1254-induced male rat liver homog-
enate; protein content 21.7 mg/mL at a concentration of 0.3 mL S9
per mL of mix for S. typhimurium strains; duration of pre-incuba-
tion period: 60 min at 37 C. This pre-incubation assay was
supplemented by a direct plate incubation test ±S9 without pre-
incubation under otherwise identical conditions. Sumitomo: pre-
incubation ±S9 from phenobarbital and 5,6-benzo ﬂavone-induced
male rat liver S9 from Oriental Yeast Co., Ltd. at a concentration of
0.1 mL S9 per mL of mix for all strains; duration of pre-incubation
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tion bacterial reverse mutation test as described above. The Ames’
tests utilized a dose-range from 0.015 to 5 mg TFL/plate (test items
dissolved in dimethyl sulfoxide, DMSO). Total bacteria counts
remained unchanged and no inhibition of growth was observed
up to the maximum dose examined. The precipitation of the test
substance was observed by unaided-eye. Cultures from all organ-
isms were prepared by overnight incubation (shaking at 37 C) of
freshly inoculated nutrient broth. All plates were allowed to solid-
ify and incubated at 37 C for approximately 48 h (Bayer: E. coli.
Sumitomo: all strains) or 72 h (S. typhimurium). After incubation,
plates were scored for the number of mutant colonies using an
automated colony counter. The number of mutant colonies of the
DMSO control group was compared with those of the test item
groups. The test substance was classiﬁed as mutagenic if there
was a dose-related increase over the range about twice of the neg-
ative control.
2.9. Bioefﬁcacy
Five samples of TFL from two alternative sources were exam-
ined for their knock-down potency in ﬁve strains of mosquitoes:
Culex quinquefasciatus, Aedes aegypti, Aedes albopictus, Anopheles
gambiae, and Anopheles funestus. The age of insects was in the range
of 3–4 days. The tests were carried out in chambers of 20 m3
(length: 3.00 m, width: 2.49 m, height: 2.69 m), inside walls, ceil-
ings and ﬂoor were of stainless steel with three windows to allow
visual inspection of the insects during the course of exposure.
Three suspended wire cages per strain with 20 mosquitoes each
(length: 8.4 cm, diameter: 8.0 cm, mesh-size: 1.0 mm), each. These
were placed in the test chamber at a height of 1.80 m with 0.45 m
distance from walls at practically equidistant positions to the
vaporizer. An electrically powered vaporizer system containing
equal amounts of TFL dissolved in kerosene was placed in the cen-
ter of the chamber and was started after chamber closure. Every
2 h additional triplicates of insect cages were hung in the room
up to 6 h. The time to attain knock-down (KT) in 50% and 95% of
each target population was examined in all cages over exposure
intervals of 2 h. The response to insects to TFL was maximal and
minimal within the 0–2 and 4–6 h intervals, respectively. The best
reﬂection of the response curve was attained at the 2–4 h exposure
period which therefore was selected for potency comparison.
Alternatively, a direct application assay in Culex pipiens pallens
was used for generics -GII and -GIII. TFL-R served as reference
(for details see Table 1).
2.10. Data analysis
The comparison of lung function data utilized a one way
repeated measures analysis of variance (RM ANOVA) preceded by
a Shapiro–Wilk normality and equal variance test followed by a
multiple comparisons versus the TFL-R group (Holm–Sidak
method). Statistical analyses were performed by Sigma Plot 12.5
(Software, Systat, Point Richmond, CA). For all tests the criterion
for statistical signiﬁcance was set at P < 0.05. Asterisks in ﬁgures
denote statistically signiﬁcant differences to the TFL-reference
group, ⁄P < 0.05 and ⁄⁄P < 0.01.Fig. 3. Comparative assessment of bioefﬁcacy of generic TFL from alternative
sources. Technical transﬂuthrin (TFL-R) was used as reference (for details see
Table 1). All tests were made under identical conditions in a 20 m3 environmental
chamber pre-loaded with Culex quinquefasciatus (Cq) or Anopheles funestus (Af). The
time to attain knock-down (KT) in 50% and 95% of the target population was
examined in triplicates with t = 0 starting 2 h after the dosing of chambers.3. Results
3.1. Bioefﬁcacy
Generic active substances from India and China were compared
for the time of attaining knock-down (KT) in ﬁve stains of mosqui-
toes. Technical transﬂuthrin (TFL-R) was used as a reference (fordetails see Table 1). The results obtained with the most susceptible
strains C. quinquefasciatus (Cq) and A. funestus (Af) are shown in
Fig. 3. For comparison, the cumulative KT50 and KT95 were exam-
ined at 2 h after switch-on the evaporation system. Based on the
cumulative KTs in these two genus of mosquitoes, the generic TFLs
were 2–3-fold less efﬁcacious than TFL-R. The alternative direct
application assay in Culex pipiens pallens demonstrated that for
attaining equal bioefﬁcacy relative to TFL-R, a 1.2-fold (TFL-GII)
and 2.4-fold (TFL-GIII) higher dose was required, respectively.
Whatever assay was applied, the results from two different labora-
tories show a reproducible lower bioefﬁcacy of the alternative
source TFLs relative to the reference TFL. It was not possible to
associate this lack in target-species bioefﬁcacy to the analytically
deﬁned racemic purity (Table 1, Fig. 3). This outcome did not jus-
tify to pursue any further more in-depth comparisons of ‘analytical
purity’ and ‘biological efﬁcacy’ as qualifying index of ‘equivalent
toxicity’.3.2. Respiratory tract sensory irritation
The acute upper/lower respiratory tract sensory irritation
potency of four different TFL-R batches from a separate ancillary
study was compared with the technical TFL-R used as current ref-
erence in this study. The relationships shown in Figs. 4 and 6
yielded identical results for both the breathing frequency and tidal
volume at concentrations when examined in the range of 200 mg/
m3. At the neuroexcitatory concentration of 400 mg/m3 the resolu-
tion of this assay decreased due to the interference of pressure
ﬂuctuations within the volume–displacement plethysmograph
caused both by fasciculations and/or tremor and breathing activi-
ties (Fig. 2).
In rats exposed at 200 mg/m3 to TFLs from alternative sources,
two out of four TFL-generics elicited changes in respiratory rate
(Fig. 5A) and tidal volume (Fig. 5C). As typically observed for sen-
sory irritants, these reﬂexively-induced changes were rapid in
onset and reversibility without time-related aggravation. Notably,
TFL-GI (low residual content of PAA, see Table 1) triggered an
increased respiratory rate with decreased tidal volume, the expo-
sure to TFL-GIV (high residual content of PAA, see Table 1) yielded
the opposite change in breathing patterns (Fig. 6). The most pro-
nounced change in tidal volume was elaborated by rats exposed
to TFL-GIV. At this exposure level all samples were tolerated with-
out clinical signs (systematic recording of signs commenced after
Fig. 4. Analysis of respiratory patterns (breathing frequency (A,B) and tidal volume (C,D)) of conscious and spontaneously breathing rats in volume displacements nose-only
plethysmographs as conceptualized in Fig. 2. Groups of rats were exposed for 45-min to equal concentrations of the vehicle PEG 400 (C) to attain either 200 or 400 mg TFL-R/
m3 (Table 3). Before and after this exposure period rats were exposed to air. Four independent samples of TFL-R were compared for ‘sensory irritation’ and ‘neuro excitation’
(ancillary study). Data points represent averages of six rats/group (±S.D.). The bar charts (E,F) represent the 15-min average of the 45–60 min exposure segment shown in (A–
D). Statistical differences to TFL-R exposed rats were not observed (P > 0.05).
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trast, at 400 mg TFL-R/m3, a few rats displayed transient reddish
encrustations at the nose/muzzle area and lacrimation for maxi-
mally 1–2 h post-exposure. Irritation-related changes in respira-
tory endpoints (Figs. 5B,D and 6) could experimentally not be
differentiated from CNS-related neuroexcitatory etiologies. Similar
conclusions hold for the current reference TFL.3.3. Respiratory sensitization
Typical immediate-onset type of respiratory reactions occurred
in the sensitized but not in the equally challenged naïve guinea
pigs (Figs. 7 and 8, upper panel). Serum IgG1 anti-PAA antibody
titers were precipitously increased in the 2.5% PAA-induction
group relative to the equally challenged vehicle group (Fig. 8, lower
panel). Histopathology of lungs and lung associated lymph nodes
revealed a marked inﬂux of eosinophilic granulocytes in PAA-
sensitized guinea pigs (data not shown), which is a commonhallmark of bronchial asthma. The concentration-dependence of
intradermally injected PAA to induce serum IgG1 anti-PAA anti-
body was additionally examined in non-challenged guinea pigs.
The transitional level for speciﬁc IgG1-antibody induction was
0.1% PAA whereas 0.01% PAA was judged to be the no-effect level
for any immunological response (Fig. 8, lower panel).3.4. Skin sensitization
Pre-technical TFL was tested in the GPMT sensitization assay as
detailed in Table 2. This study was duplicated using TFL spiked
with 1% PAA employing two challenges: the ﬁrst challenge was
with TFL-1% PAA followed by a second challenge with pre-techni-
cal TFL. While the pre-technical TFL did not provide evidence of
any skin sensitizing potential, the spiked with 1% PAA for both
induction and challenge resulted in severe redness and encrusta-
tion of the skin after the ﬁrst topical challenge in sensitized ani-
mals. When re-challenging these animals with the pre-technical
Fig. 5. Analysis of respiratory patterns (for details see legend of Fig. 4). Groups of rats were exposed to four generic versions of TFL for 45-min to targeted concentrations at
200 or 400 mg TFL/m3. Data points represent averages of four rats/group (±S.D.). The bar charts represent the 15-min average of the 45–60 min exposure segment. Asterisks
denote statistical difference to TFL-R exposed rats (⁄P < 0.05, ⁄⁄P < 0.01).
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These ﬁndings suggest that PAA is an extremely potent skin sensi-
tizing putative impurity of TFL. These results illustrate that even
traces of PAA (residual PAA in the pre-technical TFL was in the
range of 0.02%) produced slight skin reactions in PAA-sensitized
guinea pigs. However, this level of PAA was not sufﬁcient to induce
skin sensitization in the same test as well as in the Buehler test sys-
tem (Table 4).
From the comparative analyses of 9 different samples of alter-
native TFLs (of which 6 were examined using the Magnusson &
Kligman test; for details see Tables 2 and 4) in two different labo-
ratories four of the generic TFLs were unequivocally positive (GHS
sub-category 1B), one generic TFLs was sensitizing but not yet clas-
siﬁable, and one was negative (Table 4).3.5. Eye and skin irritation
Eye/skin irritation tests in rabbits demonstrated borderline to
minimal evidence of local irritation (Table 4). The sensitivity/reso-lution of this bioassay does not seem to be sufﬁcient to reveal and/
or demonstrate differences amongst different alternative source
TFLs.3.6. Genotoxicity
All 9 different samples of generic TFL were examined in the
Ames’ bacterial reverse mutation genotoxicity assay. Under the
conditions of tests used at Bayer, the generic TFLs examined using
both the direct plate incubation and the pre-incubation assays
with/without S9 were negative in all strains, independent on
whether pre-incubation was executed or not. Under the conditions
of tests used at Sumitomo, the S. typhimurium strain T100 pre-
incubation assay was positive in 2 of 5 samples of generic TFL in
the absence of S9. These test substances showed a marked dose-
dependent increase in the number of revertant colonies to over
twice of the negative control at the dose range of which the precip-
itation of the test substance was observed (Table 4).
Fig. 6. Summary of respiratory measurements depicted in Figs. 4 and 5 independent on the actual breathing zone concentration of breathing zone concentrations of TFL. The
focus of analysis is on ﬁndings occurring at the sensory irritant exposure level. Data points represent means ± S.D. of 45–60 min exposure segment from four (comparison of
generic TFLs) or six (TFL-R batch comparison).
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Due to the exploratory nature of study, not all specimens were
subjected to all bioassays. Five specimens were subjected to the
Tier I-based analyses in two different laboratories (Table 1).
Despite the exploratory character of study, the comparison of
Tables 1 and 4 demonstrate that the outcome from Tier I may
change from one laboratory from another when focusing on reac-
tive impurities. Thus, minute variations in analytical procedures
may conceal the presence of highly toxic impurities even under cir-
cumstances with the endeavor to achieve their quantiﬁcation. The
Tier II test to be indicative of PAA-related impurities was shown to
be the sensitization test with borderline sensitization potency at
0.02% and deﬁnite outcomes at >0.1% (see Tables 1 and 4 and
Fig. 9). The total content of unknown impurities was insensitive
relative to the structural alert ‘PAA’ for respiratory/skin sensitiza-
tion (Fig. 9).4. Discussion
Transﬂuthrin has both a higher vapor pressure and efﬁcacy than
many other high efﬁcacy pyrethroids registered as household
insecticide (Hill et al., 2014). Thus, TFL is particularly suited for
the application in multiple-conﬁguration emanation systems,
which utilize its favorable vapor evaporation and re-condensation
properties to repel mosquitoes and other insects. Use-patterns vary
from short-term high-level exposures (e.g., as minispray-aerosol
and biocide paper (sachet) systems to continuous emanation sys-
tems. The actual exposure phase to this active substance is compli-
cated to assess ab initio because of the complex phase equilibria
that may exist close to vapor emanation system (e.g., mosquito
coil, electric vaporizer) and/or aerosol dispersion system (e.g.,
spray-can, minispray-aerosol). These equilibria depend on the
actual concentration of TFL relative to its saturated gas-phase con-
centration (62 lg/m3 at 25 C; Vesin et al., 2013), the kinetics of
Fig. 7. Changes in respiratory minute volumes of guinea pigs naïve or intradermally induced with permethrinic acid anhydride (PAA) followed by inhalation challenge to
PAA-haptenated guinea pig serum albumin (GPSA). Mathematical analysis of respiratory response (see also Fig. 8): from data recorded during the 15-min pre-challenge base-
line exposure period (averaging period 45 s per data point), the mean (solid line) ± 3  S.D. (dotted lines) for each guinea pig were calculated and scaled to the duration of the
inhalation challenge (30 min). The area under the curve (AUC) of the breathing response exceeding the mean + 3  S.D. was integrated from the start of challenge up to the
end of the 30-min post-challenge period (for details see Fig. 8).
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coagulation and sedimentation. Thus, actual exposure patterns to
reactive intermediates with differing physicochemical properties
are difﬁcult to deﬁne relative to the active substance. Therefore,
safe threshold concentrations of proven critical impurities such
as anhydrides should be dealt with conservatively. Their presence
as reactive vapor or as vapor partitioned to the aerosol phase
makes it also difﬁcult to pre-determine the initial site of deposition
and injury to the respiratory tract. Thus, phase- and reactivity-
wise, such yet chemically reactive impurities are challenging to
quantify both analytically (Tier I) and toxicologically (Tier II). Prior
knowledge on any process-speciﬁc pattern of impurities, either
from starting materials or newly formed, would support any ‘struc-
tural-alert’-based driven Tier I and II approach. This case studydemonstrates the beneﬁts of a ‘knowledge-based’ case-by-case
approach vs. the standard regulatory approach which com-
monly underappreciates the unique susceptibility of the respira-
tory tract.
Alternative deﬁnitions of ‘‘impurity’’ are available for low-
molecular weight active substances (Snodin and McCrossen,
2012). Its precise deﬁnition depends on the particular context
and is often classiﬁed by type (organic, inorganic, solvent), origin
(starting materials, by-products), and process of production and
puriﬁcation. Eliminating all impurities from any marketed product
is essentially impossible for both practical and economic reasons;
even a compound with high chromatographic purity in a bench-
scale process will, no doubt, contain some impurities. Con
sequently, a signiﬁcant degree of pragmatism is required when
Fig. 8. Upper panel: Area under the curve as an integrated reﬂection of immediate-
onset hyper sensitivity response in non-sensitized and challenged (naïve) and
sensitized and challenged (PAA-2.5%) guinea pigs (for details see legend of Fig. 7).
Determination of anti-IgG1-speciﬁc PAA-antibodies using an ELISA assay. The
boundary of the box closest to zero indicates the 25th percentile, the line within the
box marks the median, and the box farthest from zero indicates the 75th percentile.
Whiskers above and below the box indicate the 90th and 10th percentile. Individual
data are illustrated as open circles. Lower panel: antibody titers of guinea pigs
sensitized intradermally with PAA (2.5% – inhalation challenge group or 0.1 and
0.01% – antibody only).
J. Pauluhn, K. Ozaki / Regulatory Toxicology and Pharmacology 71 (2015) 78–92 89dealing with impurity issues. This led to the introduction of the
term ‘‘relevant impurities’’ (ECHA, 2013; Snodin and McCrossen,
2012), with the connotation as being ‘‘more or differently toxic’’Table 4
Summary of toxicological ﬁndings.











#/#: fractional change in respiratory rate/tidal volume relative to TFL-R within the 15–60
changes are attributed to ‘upper respiratory tract sensory irritation’ for respiratory rate a
recorded changes are attributed to ‘neuro excitation’. –: not examined.
a http://www.who.int/whopes/quality/Transﬂuthrin_eval_only_Nov2006.pdf.
b A positive outcome is deﬁned by changes in breathing rate and/or tidal volume exce
Fig. 6).
c Percent of animals scored positive.
d : Negative, +: slight irritation.than the pure active ingredient raising additional toxicological
concerns.
In the context of pesticide active ingredients, an impurity is
regarded as signiﬁcant if it occurs or potentially occurs in a quan-
tity P0.1% in the substance as manufactured. A signiﬁcant impu-
rity may be considered relevant or non-relevant depending, in
particular, on its known toxicological properties. Hence, an impu-
rity may be relevant even if it occurs in a quantity <0.1%. Where
new impurities are present at >0.1%, supporting data are needed
to demonstrate that these impurities are relevant or non-relevant.
There should be no change in the assessment in those studies
which produce categorical results (e.g., category 1, 2, or 3 skin irri-
tant, not a skin irritant). The same may apply for respiratory tract
irritants or sensitizers. Notably, most of the standard bioassays
used to demonstrate equivalence focus on systemic exposure and
are believed to have limited resolution to identify and quantify
the impact of highly reactive impurities likely to be recurrently
inhaled under the conditions of use (FAO and WHO, 2010).
For complex active substances, such as pyrethroids, ‘chemical
purity’ needs to be re-deﬁned as ‘biologically relevant purity’.
Alternative source pyrethroid-based pesticides are often sold and
used in the form of racemic mixtures. The use of low efﬁcient or
ineffective isomers of the racemic mixtures cannot effectively con-
trol insect pests, resulting in the waste of resources, reduce the
quality of commercialized products, and may lead to toxic side
effects with serious impact on human health (FAO and WHO,
2010; Wu et al., 2011). It is therefore of great signiﬁcance not to
deﬁne ‘purity’ as the sum of chiral enantiomers rather than focus-
ing on the bioefﬁcient enantiomer only. Bearing in mind that the
content of the active ingredient contained in household insecticide
products is adjusted to attain the targeted bioefﬁcacy, the margin
of safety of less bioefﬁcient generic products may further decrease
due to increased indoor exposure levels.
Most of the alternative source TFLs compared in this study had
‘chemical purities >95% (Table 1); however, the insecticidal active
R-enantiomer of TFL ranged from 48% to 98% in the samples exam-
ined. Toxicological equivalence is even more complex to deﬁne and
depends on speciﬁc pharmacological and/or toxicological proper-
ties and associated mode(s) of action (systemic vs. local), the pre-
vailing exposure route, including the exposure duration of the
involved population. Reactive impurities may decompose while
dissolving the active substance in the polar solvents commonly
used in bioassays. False positive outcomes can occur by the inter-
action of reactive moieties with DMSO as demonstrated in the
Ames’ assay (Snodin, 2010; Herbold et al., 1998). Positive resultsSensitization maximization test Bacterial reverse mutation test




Positive (100%)c (GHS:category 1B) Negative
Positive (100%) (GHS:category 1B) Negative
Positive (10%) (GHS:not classiﬁed) Positive (TA100 without S9)
Positive (50%) (GHS:category 1B) negative
Negative (0%) (GHS:not classiﬁed) Positive (TA100 without S9)
Positive (32%) (GHS:category 1B) Negative
min exposure period to the aerosolized substance. At the low exposure level these
nd ‘lower respiratory tract irritation’ for tidal volume. At the high exposure level the
eding the mean ± S.D. of both TFL-R and the 4-batch average at 200 mg TFL/m3 (see
Fig. 9. Comparison of the percentage of ‘unknown impurities’ and permethrinic
acid anhydride relative to the percentage of responding animals in the Magnusson
& Kligman Guinea pig maximization test (GPMT) skin sensitization assay. Dotted
line: qualiﬁcation threshold for relevant impurities (<0.1%).
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of S9 mix containing 30% S9 fraction. Uniformly negative results
were found when the diisocyanates were dissolved in ethylenegly-
coldimethylether. Decomposition may also occur in Tier I assays,
e.g., in the injection port or column of the chromatography system
applied for chemical analysis (in case the analyst would not check
this out using spiking techniques with well characterized reference
compounds). When inhaled, reactive moieties may exert a direct,
portal-of-entry-speciﬁc toxicity in the absence of any ﬁrst-pass
detoxiﬁcation. Hence in vivo (bio)assays have the inherent bias to
produce a false negative outcome due to direct protein binding
(scavenging) and/or ﬁrst-pass hydrolysis when using administra-
tion conditions/routes different from those humans are subjected
to. Anhydrides per sewere shown to be potent skin and respiratory
tract sensitizers (Pauluhn, 2003a, 2014; Pauluhn and Mohr, 2005;
Pauluhn et al., 1999, 2002; Tarlo et al., 2011). The combined
skin/inhalation exposure (Vesin et al., 2013) may further increase
the asthmagenic potency of this impurity.
Permethrinic acid anhydride (PAA) and PA-acid chloride are
highly toxic and pulmonary irritant process intermediates or by-
products in manufacturing processes of many pyrethroids. The
acute inhalation 4-h median lethal concentrations (LC50) of PAA)
and PA-acid chloride in rats were 0.22 and 0.007 mg/L, respectively
(unpublished data). As illustrated in Fig. 8, the NOAEL for IgG1-
anti-PAA antibody induction was 0.01% which translates to
approximately 30 lg PAA/kg guinea pig. However, any quantitative
risk characterization for PAA based on this endpoint is hampered
by the fact that the ‘immunological purity’ of the synthesized
PAA-guinea pig serum protein conjugate used in the ELISA assay
cannot readily be judged or put into any more quantitative expo-
sure perspective. As demonstrated by Vesin et al. (2013), only
about 10% of the nominally discharged TFL from vaporizing sys-
tems was recovered airborne. The more volatile solvent contained
in such systems, e.g., isoparafﬁns, may act as carrier for reactive
impurities into room air. Based hereupon, an exposure-dependent
enrichment of the impurity content of the active substance and
that present in indoor air cannot be ruled out.
The study focused on the comparative assessment and power of
highly speciﬁc analytical assays relative to integrating bioassays at
two different laboratories experienced with regulatory standards
and Good Laboratory Practice Principles. No prior emphasis
was made to ‘pre-calibrate’ these laboratories in order to arriveat identical outcomes. Rather each laboratory was allowed to
execute each test according to best practice, past in-house experi-
ence as called for by internationally harmonized OECD testing
guidelines. Under the applied conditions, any equal outcome
would be a reﬂection of robustness and reproducibility.
Physiological tests (lung function) have the beneﬁt of being
instant and quantiﬁable. However, it has to be recalled that these
assays may have limited resolution to identify speciﬁcally the ‘nee-
dle in the haystack’. Despite these shortcomings, past measure-
ments with different TFL-R batches (ancillary study) with the
currently used TFL-R demonstrated remarkable reproducibility
(Figs. 4 and 6). Two out of four examined TFL-generic versions
caused unequivocal changes in breathing patterns (Figs. 5 and 6)
suggestive of the presence of a lung-irritant impurity which was
unequivocally absent in TFL-R. Notably, the signal measured in vol-
ume-displacement plethysmographs is pressure ﬂuctuation, which
can also be superimposed by the neuroexcitatory activity (e.g., tre-
mor, fasciculations, convulsions) of the active substance (as shown
at the high-exposure level). Therefore, dose-selection is of para-
mount importance to differentiate sensory irritation-related from
neuroexcitatory stimulation-related pressure ﬂuctuations. Sensiti-
zation is biologically far more complex than irritation. A high sen-
sitizing potency was shown for both inhalation and dermal
exposures in the proof-of-principle study using TFL spiked with
PAA. This causality was not found at the Tier I level at the ﬁrst
place. However, a subsequently reﬁned Tier I-level re-analysis
using an external PAA-reference standard, its presence was analyt-
ically veriﬁed. The Tier I and II results given in Tables 1 and 4 dem-
onstrate convincingly that both Tiers need to be integrated into
each other to minimize ‘false negative’ conclusions to occur.
The potential health impact originating from impurities is fre-
quently assessed by threshold of toxicological concern (TTC) anal-
yses, an estimate below which no appreciable risk to human health
is expected to occur under well-deﬁned end-use conditions (Kroes
et al., 2005). The TTC approach relates only to systemic effects and,
at present, cannot be used for the assessment of local effects.
Allergy, hypersensitivity and intolerance are excluded due to
uncertain dose–response data (SCCP, 2012). Hence, especially for
inhaled substances containing reactive impurities, the combined
adversity originating from local irritation, allergy/hypersensitivity,
and genotoxicity cannot reliably be predicted or assessed in the
absence of inhalation data. Published evidence suggests that the
body weight-adjusted NOAELs from repeated inhalation studies
with active substances (agrochemicals) were up to 10-fold lower
than their oral/dietary counterparts for systemically acting pesti-
cides. However, in case the pesticide had an additional ‘local mode
of action’, then the NOAELs were even 10- to 500-fold lower than
the respective oral/dietary NOAEL for systemic toxicity (see Fig. 5
in Pauluhn, 2003b). Cumulative safety factors in the range of
100–1000 from the NOAEL (or point of departure) from animal
studies reﬂecting the human exposure pattern best are most fre-
quently used to derived safe levels with no appreciable risk to
human health (general population). This comparison supports the
notion that oral-to-inhalation extrapolation of direct acting, data
lean inhaled impurities are biased to result in erroneous conclu-
sions. When either the potency and/or the content of the impurity
of an alternative source (generic) active substance is high enough
to affect the toxicity proﬁle and/or the categorization/classiﬁcation
of the non-irritant, non-genotoxic, and non-sensitizing reference
source active substance (Table 4), integrated hazard considerations
(Tier II-based) are given preference to preemptive ‘total daily
dose’-based TTC considerations (Tier I-based). This approach seems
not to be at variance with that recommended in the respective
guidance document for technical equivalence of ECHA (2012,
2013) and matches also the deliberations of other expert commit-
tees (SCCP, 2012). In regulatory context, technical equivalence
J. Pauluhn, K. Ozaki / Regulatory Toxicology and Pharmacology 71 (2015) 78–92 91means similarity, as regards the chemical composition and hazard
proﬁle, of a substance produced either from a source different to
the reference source, or from the reference source but following
a change to the manufacturing process and/or manufacturing loca-
tion, compared to the substance of the reference source in respect
of which the initial risk assessment was carried out. If a new,
highly reactive impurity of toxicological concern in the alternative
source has not been established for the reference source, due to a
different production and puriﬁcation process, only the Tier II
approach may reveal this circumstance as exempliﬁed in this
exploratory study.
In summary, with regard to the generic versions of TFL one may
conclude that each batch even from the same alternative producer
differed markedly in terms of bioefﬁcacy and the presence of
‘unusually potent impurities’. These impurities could only be iden-
tiﬁed analytically with the Tier II-driven knowledge in terms of
their identiﬁcation as such, limit of detection, and speciﬁcity. As
evidenced in Tables 1 and 4, impurity proﬁle analysis serves an
important purpose in determining the quality aspects of any well
characterized active substance and critical impurities. This infor-
mation may not necessarily apply for alternative source TFLs due
to their modiﬁed production process-related ‘new toxicological
entities’. This outcome supports the overall conclusion that Tier I
and II approaches have to be used in concert rather than in isola-
tion. The expert knowledge- and MoA-based Tier II feedback-loop
is considered to be an indispensable attribute to demonstrate
equivalence of products used as household insecticides.Declaration of conﬂict of interest
There is no conﬂict of interests. Bayer CropScience is a producer
of the innovative Transﬂuthrin (TFL-R) used in this study. Sumito-
mo Chemicals is a distributor of TFL-R in Japan.
References
Draize, J.H., Woodard, G., Calvery, H.O., 1944. Method for the study of irritation and
toxicity of substances applied topically to the skin and mucus membranes. J.
Pharmacol. Exp. 82, 377–390.
EEC, 2011. European Commission, Health & Consumer Protection Directorate-
General, Directorate E – Safety of the Food Chain, E3 – Chemicals, Contaminants
and Pesticides: Guidance Document on the Assessment of the Equivalence of
Technical Materials of Substances Regulated under Regulation (EC) No. 1107/
2009 SANCO/10597/2003, rev. 9. 17 June 2011.
ECHA, 2012. Guidance on information requirements and chemical safety
assessment chapter R.8: characterisation of dose [concentration]–response for
human health. Available at: <http://echa.europa.eu/documents/10162/13632/
information _requirements_r8_en.pdf>.
ECHA, 2013. Guidance on applications for technical equivalence Guidance on
Regulation (EU) No 528/2012 concerning the making available on the market
and use of bocidal products, Version 1.0, August 2013.
FAO and WHO, 2010. Manual on development and use of FAO and WHO
speciﬁcations for pesticides, November 20, 2010, Prepared by the FAO/WHO
Joint Meeting on Pesticide Speciﬁcations (JMPS), World Health Organization
Food and Agriculture Organization of the United Nations, Rome. Available at:
<http://www.fao.org/3/a-y4353e.pdf>.
GHS, 2013. UNECE (United Nations Economic Commission for Europe): Globally
Harmonized System of Classiﬁcation and Labelling of Chemicals (GHS), Fifth
revised edition, Part 3: Health Hazards. GHS (Rev.5), 2013. Available at: <http://
www.unece.org/ru/trans/danger/publi/ghs/ghs_rev05/05ﬁles_r.html>.
Hill, N., Zhou, H.N., Wang, P., Guo, X., Carneiro, I., Moore, S.J., 2014. A household
randomized, controlled trial of the efﬁcacy of 0.03% transﬂuthrin coils alone and
in combination with long-lasting insecticidal nets on the incidence of
Plasmodium falciparum and Plasmodium vivax malaria in Western Yunnan
Province, China. Malar. J. 13, 208.
Herbold, B., Haas, P., Seel, K., Walber, U., 1998. Studies on the effect of the solvents
dimethylsulfoxide and ethyleneglycoldimethylether on the mutagenicity of
four types of diisocyanates in the Salmonella/microsome test. Mutat. Res. 30
(412), 167–175.
Kroes, R., Kleiner, J., Renwick, A., 2005. Forum: the threshold of toxicological
concern concept in risk assessment. Toxicol. Sci. 86, 226–230.Li, W.L., Pauluhn, J., 2010. Comparative assessment of the sensory irritation potency
in mice and rats nose-only exposed to ammonia in dry and humidiﬁed
atmospheres. Toxicology 276, 135–142.
Naumann, K. (Ed.), 1990. Synthetic Pyrethroid Insecticides: Formation of the
Pyrethroid-Ester-Linkage, Chemistry and Patents Chemistry of Plant Protection,
vol. 5. Springer Verlag, Weinheim (pp. 129–173).
Magnusson, B., 1980. Identiﬁcation of contact sensitizers by animal assay. Contact
Dermatitis 6, 46–50.
Magnusson, B., Kligman, A.M., 1969. The identiﬁcation of contact allergens by
animal assay. The guinea pig maximization test. J. Invest. Dermatol. 52, 268–
276.
OECD, 1992. Guideline for the Testing of Chemicals #406. Skin Sensitization.
Environment Directorate, Organization for Economic Cooperation and
Development, July 17, 1992. Available at: <http://ntp.niehs.nih.gov/iccvam/
suppdocs/feddocs/oecd/oecdtg406.pdf>.
OECD, 2009. Environment, Health and Safety Publications, Series on Testing and
Assessment #39: Guidance Document for Acute Inhalation Toxicity Testing,
[ENV/JM/MONO 28, July 21, 2009, 71 pp.]. Available at: <http://www.oecd.org/
document/30/0,3343,en_2649_34377_1916638 _1_1_1_1,00.html>.
OECD, 2002. Guidelines for the Testing of Chemicals, Section 4, Health Effects Test
#405: Acute Eye Irritation/Corrosion.
OECD, 1992. Guidelines for the Testing of Chemicals, Section 4, Health Effects Test
#406: Skin Sensitization. Available at: <http://www.oecd-ilibrary.org/
environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-
effects_20745788>.
OECD, 1997. Guidelines for the Testing of Chemicals, Section 4, Health Effects Test
#471: Bacterial Reverse Mutation Test. Available at: <http://www.oecd-
ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-
4-health-effects_20745788>.
Pauluhn, J., Mohr, U., 1994. Assessment of respiratory hypersensitivity in Guinea
pigs sensitized to diphenylmethane-4,40-diisocyanate (MDI) and challenged
MDI, acetyl choline or MDI-albumin conjugate. Toxicology 92, 53–74.
Pauluhn, J., 1997. Assessment of respiratory hypersensitivity in Guinea pigs
sensitized to toluene diisocyanate: improvements on analysis of response.
Fundam. Appl. Toxicol. 40, 211–219.
Pauluhn, J., Mohr, U., 1998. Assessment of respiratory hypersensitivity in Guinea
pigs sensitized to toluene diisocyanate: a comparison of sensitization protocols.
Inhal. Toxicol. 10, 131–154.
Pauluhn, J., Dearman, R., Doe, J., Hext, P., Landry, T.D., 1999. Respiratory
Hypersensitivity to Diphenyl methane-4,40-diiso cyanate in Guinea-pigs:
Comparison with Trimellitic Anhydride. Inhal. Toxicol. 11, 187–214.
Pauluhn, J., Eidmann, P., Freyberger, A., Wasinska-Kempka, G., Vohr, H.-W., 2002.
Respiratory Hypersensitivity to Trimellitic Anhydride in Brown Norway Rats: A
comparison of endpoints. J. Appl. Toxicol. 22, 89–97.
Pauluhn, J., 2003a. Respiratory Hypersensitivity to Trimellitic Anhydride in Brown
Norway Rats: Analysis of Dose–Response following topical Induction and Time
Course following Repeated Inhalation Challenge. Toxicology 194, 1–17.
Pauluhn, J., 2003b. Issues of dosimetry in inhalation toxicity. Toxicol. Lett. 140–141,
229–238.
Pauluhn, J., 2005. Retrospective analysis of acute inhalation toxicity studies:
comparison of actual concentrations obtained by ﬁlter and cascade impactor
analyses. Regul. Toxicol. Pharmacol. 42, 236–244.
Pauluhn, J., Mohr, U., 2005. Review. Experimental approaches to evaluate
respiratory allergy in animal models. Exp. Toxicol. Pathol. 56, 203–234.
Pauluhn, J., Thiel, A., 2007. A simple approach to validation of directed-ﬂow nose-
only inhalation chambers. J. Appl. Toxicol. 27, 160–167.
Pauluhn, J., 2014. Development of a respiratory sensitization/elicitation protocol of
toluene diisocyanate (TDI) in brown Norway rats to derive an elicitation-based
occupational exposure level. Toxicology 319, 10–22.
Snodin, 2010. Genotoxic impurities: from structural alert to qualiﬁcation. Org.
Process Res. Dev. 14, 960–976.
Snodin, D.J., McCrossen, S.D., 2012. Guidelines and pharmacopoeial standards for
pharmaceutical impurities: overview and critical assessment. Regul. Toxicol.
Pharmacol. 63, 298–312.
SCCP, 2012. Opinion on Use of the Threshold of Toxicological Concern (TTC)
Approach for Human Safety Assessment of Chemical Substances with focus on
Cosmetics and Consumer Products. The SCCS/SCHER/SCENIHR adopted this
opinion by written procedure on 8 June 2012 after public consultation (SCCP/
1171/08). Available at: <http://ec.europa.eu/health/scientiﬁc_committees/
consumer_safety/docs/sccs_o_092.pdf>.
Tarlo, S., Cullinan, P., Nemery, B., 2011. Occupational and Environmental Lung
Diseases: Diseases from Work, Home, Outdoor and Other Exposures (Google
eBook), 18.3.4. Acid Anhydrides. John Wiley & Sons.
US-EPA, 1998. Ofﬁce of Prevention, Pesticides and Toxic Substances (OPPTS) #870-
2400: Acute Eye Irritation. Available at: <http://www.epa.gov/ocspp/pubs/frs/
publications/Test_Guidelines/series870.htm>.
US-EPA, 1998. Ofﬁce of Prevention, Pesticides and Toxic Substances (OPPTS) #870-
2500: Acute Dermal Irritation. Available at: <http://www.epa.gov/ocspp/pubs/
frs/publications/Test_Guidelines/series870.htm>.
US-EPA, 2003. Ofﬁce of Prevention, Pesticides and Toxic Substances (OPPTS) #870-
2500: Skin Sensitization. Available at: <http://www.epa.gov/ocspp/pubs/frs/
publications/Test_Guidelines/series870.htm>.
Vesin, A., Glorennec, P., Le Bot, B., Wortham, H., Bonvallot, N., Quivet, E., 2013.
Transﬂuthrin indoor air concentration and inhalation exposure during
application of electric vaporizers. Environ. Int. 60, 1–6.
92 J. Pauluhn, K. Ozaki / Regulatory Toxicology and Pharmacology 71 (2015) 78–92Wu, Y., Miao, H., Fan, S., 2011. Chapter 8: separation of chiral pyrethroid pesticides
and application in pharmacokinetics research and human exposure assessment
in agricultural and biological sciences. In: Margarita Stoytcheva (Ed.), Pesticides
in the Modern World – Effects of Pesticides Exposure. ISBN 978-953-307-454-2,September 12, 2011 under CC BY-NC-SA 3.0 license. Open access available at:
<http://www.intechopen.com/books/pesticides-in-the-modern-world-effects-
of-pesticides-exposure/separation-of-chiral-pyrethroid-pesticides-and-application-
in-pharmacokinetics-research-and-human-ex>.
